# US 2021/0330718 A1 · Composition and methods for treating cancer and immune disorders using veillonella bacteria > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2021/0330718 A1 - Document ID: US20210330718A1 - Status: Published application - Kind: A1 - Application number: 17/368,396 - Filed: 2021-07-06 - Published: 2021-10-28 - Earliest claimed: 2018-02-06 - Assignees: Evelo Biosciences, Inc. - Applicants: Evelo Biosciences, Inc. - Inventors: Brian Goodman; Baudauna Bose; Christopher J. Davitt; Maria Sizove; Sofia M. Carlton; Andrea Itano; Holly Ponichtera; Taylor A. Cormack; Kritika Ramani - Web page: https://patentgrep.com/patent/US20210330718A1 ## CPC - A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00) - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics - A61P 3/10: for hyperglycaemia, e.g. antidiabetics - A61P 17/06: Antipsoriatics - A61P 19/02: for joint disorders, e.g. arthritis, arthrosis - A61P 35/00: Antineoplastic agents - A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection - C07K 16/2818: {against CD28 or CD152} - C12N 1/20: Bacteria; Culture media therefor - C12N 1/205: Bacterial isolates - A61K 2039/505: {comprising antibodies} - C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales} - Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract Provided herein are methods and compositions related to Veillonella bacteria useful as therapeutic agents. ## Claims ### Claim at position 1 1-161. (canceled) ### Claim 162 A method of treating an immune disorder in a subject comprising orally administering to the subject a pharmaceutical composition comprising Veillonella parvula Strain B (ATCC Accession Number PTA-125691) and a pharmaceutically acceptable carrier. ### Claim 163 (depends on 162) The method of claim 162, wherein the Veillonella parvula Strain B (ATCC Accession Number PTA-125691) and the pharmaceutically acceptable carrier are within an enteric coating. ### Claim 164 (depends on 162) The method of claim 162, wherein the immune disorder is atopic dermatitis, psoriasis, or asthma. ### Claim 165 (depends on 162) The method of claim 162, wherein at least 50% of the bacteria in the pharmaceutical composition are Veillonella parvula Strain B (ATCC Accession Number PTA-125691). ### Claim 166 (depends on 162) The method of claim 162, wherein at least 95% of the bacteria in the pharmaceutical composition are Veillonella parvula Strain B (ATCC Accession Number PTA-125691). ### Claim 167 (depends on 162) The method of claim 162, wherein at least 99% of the bacteria in the pharmaceutical composition are Veillonella parvula Strain B (ATCC Accession Number PTA-125691). ### Claim 168 (depends on 162) The method of claim 162, wherein the pharmaceutical composition comprises at least 1×106 colony forming units (CFUs) of Veillonella parvula Strain B (ATCC Accession Number PTA-125691. ### Claim 169 (depends on 162) The method of claim 162, wherein the pharmaceutical composition comprises live bacteria. ### Claim 170 (depends on 162) The method of claim 162, wherein the pharmaceutical composition comprises killed bacteria. ### Claim 171 (depends on 162) The method of claim 162, wherein the pharmaceutical composition comprises irradiated bacteria. ### Claim 172 (depends on 171) The method of claim 171, wherein the irradiated bacteria comprises gamma irradiated bacteria. ### Claim 173 (depends on 163) The method of claim 163, wherein the pharmaceutical composition is formulated as an enteric coated capsule. ### Claim 174 (depends on 163) The method of claim 163, wherein the pharmaceutical composition is formulated as an enteric coated tablet. ### Claim 175 (depends on 163) The method of claim 163, wherein the enteric coating is a coating for duodenal release at a pH of about 5.5-6.2. ### Claim 176 (depends on 163) The method of claim 163, wherein the enteric coating is a coating for release in the ileum at a pH of about 7.2-7.2. ### Claim 177 (depends on 163) The method of claim 163, wherein the enteric coating is a coating for release in the colon at a pH of about 5.6-7.2. ### Claim 178 (depends on 162) The method of claim 162, wherein the Veillonella parvula Strain B (ATCC Accession Number PTA-125691) is freeze-dried. ### Claim 179 (depends on 62) The method of claim 62, wherein the method further comprises administering to the subject an additional therapeutic. ### Claim 180 (depends on 179) The method of claim 179, wherein the additional therapeutic is an antibiotic. ### Claim 181 (depends on 179) The method of claim 179, wherein the additional therapeutic is an anti-inflammatory agent.